Market Snapshot

BSE Sensex: 85267.66 0.53%
BSE 500: 37228.82 0.72%
BSE 200: 11752.7 0.68%
BSE 100: 27246.8 0.61%
BSE MidCap: 46477.51 1.14%
BSE SmallCap: 50890.67 0.65%
BSE BANKEX: 66662.68 0.30%
BSE IT: 37004.68 0.45%
Nifty 50: 26046.95 0.57%
Nifty 500: 23726.2 0.74%
Nifty 200: 14469.3 0.72%
Nifty 100: 26565.1 0.62%
Nifty Midcap 100: 60283.3 1.18%
Nifty Small 100: 17389.95 0.94%
Nifty IT: 38274.75 0.47%
Nifty PSU Bank: 8247.8 0.15%

News:

United Drilling Tools secures ...
Biocon?s arm inks pact to comm...
GPT Infraprojects secures Rs 5...
KEC International bags Rs 1,15...
Astra Microwave Products bags ...

Concord Biotech Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

12 Dec 2025 | 03:59 PM

1,370.55

0.85 (0.06%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Underperforms Index

-35.84%

Return (1Y)

Underperformed BSE Healthcare by 35.64%
More Volatile

2.8%

Standard Deviation (1Y)

Higher than BSE Healthcare by 1.84%
Inconsistent Performer

3/12

Months

underperformed BSE Healthcare
AxisDirect View

No View

52 Week High-Low

2,452

1,334

News & Announcements

Concord Biotech consolidated net profit declines 33.59% in the September 2025 quarter
28 days ago

Concord Biotech consolidated net profit declines 33.59% in the September 2025 quarter

15 - Nov - 2025 12:00 | 28 days ago

Net profit of Concord Biotech declined 33.59% to Rs 63.58 crore in the quarter ended September 2025 as against Rs 95.74 crore during the previous quarter ended September 2024. Sales declined 20.35% to Rs 247.06 crore in the quarter ended September 2025 as against Rs 310.18 crore during the previous quarter ended September 2024.

Particulars Quarter Ended
Sep. 2025 Sep. 2024 % Var.

Sales 247.06 310.18 -20

OPM % 35.82 43.11 -

PBDT 104.08 143.65 -28

PBT 85.68 130.34 -34

NP 63.58 95.74 -34

Powered by Capital Market - Live News
Concord Biotech standalone net profit declines 36.27% in the September 2025 quarter
28 days ago

Concord Biotech standalone net profit declines 36.27% in the September 2025 quarter

15 - Nov - 2025 12:00 | 28 days ago

Net profit of Concord Biotech declined 36.27% to Rs 62.90 crore in the quarter ended September 2025 as against Rs 98.70 crore during the previous quarter ended September 2024. Sales declined 20.35% to Rs 247.06 crore in the quarter ended September 2025 as against Rs 310.18 crore during the previous quarter ended September 2024.

Particulars Quarter Ended
Sep. 2025 Sep. 2024 % Var.

Sales 247.06 310.18 -20

OPM % 36.65 44.06 -

PBDT 103.92 146.60 -29

PBT 85.53 133.29 -36

NP 62.90 98.70 -36

Powered by Capital Market - Live News
Concord Biotech announces board meeting date
35 days ago

Concord Biotech announces board meeting date

08 - Nov - 2025 12:00 | 35 days ago

Concord Biotech will hold a meeting of the Board of Directors of the Company on 13 November 2025.
Powered by Capital Market - Live News
Concord Biotech gains after successful EU-GMP inspection at Limbassi facility
114 days ago

Concord Biotech gains after successful EU-GMP inspection at Limbassi facility

21 - Aug - 2025 12:00 | 114 days ago

The inspection was conducted by EU-GMP authorities from 18 August to 21 August 2025. The company stated that this milestone marks a significant achievement, as the successful outcome not only validates its commitment to global quality standards but also opens avenues to expand its presence in international markets.
The EU-GMP approval will allow Concord to explore commercial opportunities across multiple EU territories and other regulated geographies, strengthening its global footprint and supporting its growth strategy.
Concord added that the inspection outcome reaffirms its commitment to the highest standards of quality, safety, and regulatory compliance, highlighting its focus on operational excellence and alignment with international regulatory expectations.
Concord Biotech is involved in manufacturing fermentation and semi-synthetic biopharmaceutical APIs with immunosuppressants as its key therapeutic segment.
The company's consolidated net profit fell 26.1% to Rs 44.06 crore on a 5.5% decline in revenue from operations to Rs 203.99 crore in Q1 FY26 over Q1 FY25.
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

Concord Biotech Ltd is trading very close to its 52 Week Low
FII shareholding in Concord Biotech Ltd has decreased by -11.79% since past 3 Months
MF shareholding in Concord Biotech Ltd has decreased by -3.26% since past 3 Months
MF shareholding in Concord Biotech Ltd has decreased by -8.83% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	247.06	310.18	-20
OPM %	35.82	43.11	-
PBDT	104.08	143.65	-28
PBT	85.68	130.34	-34
NP	63.58	95.74	-34

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	247.06	310.18	-20
OPM %	36.65	44.06	-
PBDT	103.92	146.60	-29
PBT	85.53	133.29	-36
NP	62.90	98.70	-36

General Notifications

My Notifications

Research Notifications

Concord Biotech Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

1,370.55 0.85 (0.06%)

News & Announcements

Price vs Volume

Stock Trivia

Concord Biotech Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

1,370.55

0.85 (0.06%)